we have used recombinant human erythropoietin (r-huepo) in children with chronic renal failure. there was significant improvement in anemia and wellbeing, along with regression of left ventricular mass and no change in the rate of decline of renal function. it is safe and effective in the pre-dialysis as well as the hemodialysis period. considering the benefits of r-huepo, transplantation in ch...

serum erythropoietin (epo) concentration was measured by an enzyme-linked immunosorbent assay (elisa) in 31 cases of chronic renal failure (crf), including 20 hemodialysis (hd) patients, and compared with that of 31 healthy normal controls. each patient served as a self-control comparing his or her pretreatment level with post-treatment values. there was a significant negative correlation betwe...

The pharmacokinetics of recombinant human erythropoietin (rHuEpo) administered intravenously has been investigated in a group of five patients with chronic renal failure who were dialysis-dependent. The half-life of circulating erythropoietin decreased from 7.9±OA hr (mean ±SO) at the beginning of treatment to 6.2±O.6 hr after 6 weeks and 5A±O.9 hr after 4 months of treatment. In spite of t...

the pharmacokinetics of recombinant human erythropoietin (rhuepo) administered intravenously has been investigated in a group of five patients with chronic renal failure who were dialysis-dependent. the half-life of circulating erythropoietin decreased from 7.9±oa hr (mean ±so) at the beginning of treatment to 6.2±o.6 hr after 6 weeks and 5a±o.9 hr after 4 months of treatment. in spite of the s...

introduction: chronic renal disease (c.r.d) is a pathophysiological process due to progressive and irreversible decrease in number and function of nephrons in the kidney. anemia is one of the most important complications in crd patients. anemia is caused mainly due to diminished production of erythropoietin (epo), which is treated by weekly injection of the epo. l-carnitine added to epo can inc...

et al. Improved sexual function during recombinant human erythropoietin therapy. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [see comments]. Valderrabano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patie...

background: acute renal failure describes as a syndrome by rapid decline in the ability of the kidney to eliminate waste products, regulate acid–base balance, and manage water homeostasis. when this impairment is prolonged and entered chronic phase, erythropoietin secretion by this organ is decreasing and toxic metabolic accumulates and causes hematological changes include decrease of hct, mcv ...

We have used recombinant human erythropoietin (r-HuEPO) in children with chronic renal failure. There was significant improvement in anemia and wellbeing, along with regression of left ventricular mass and no change in the rate of decline of renal function. It is safe and effective in the pre-dialysis as well as the hemodialysis period. Considering the benefits of r-HuEPO, transplantation i...

Currently many patients with chronic renal failure have profited from the use of erythropoietin to correct anemia (1,2). In chronic kidney disease, anemia is believed to be a surrogate index for tissue hypoxia that continues preexisting renal tissue injury (1-3). Erythropoietin is an essential glycoprotein that accelerates red blood cell maturation from erythroid progenitors and facilitates ery...